Stay updated on Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial

Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision: v3.4.1 is now displayed, replacing the previous v3.4.0. This is a minor site metadata update and does not alter the study details.
    Difference
    0.1%
    Check dated 2026-02-04T23:43:09.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Show glossary added and ORR/DCR definitions updated to RECIST 1.1 criteria with duration notes (e.g., 'Throughout study duration, up to approx 80 months'). Additionally, metadata updates were added, including 'Last Update Submitted that Met QC Criteria', 'Revision: v3.4.0', and 'No FEAR Act Data'.
    Difference
    0.8%
    Check dated 2026-01-28T19:50:42.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page revision label changed from v3.3.3 to v3.3.4, a minor metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T04:00:47.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    Added a dedicated Locations section with New York as a site; the old New York Locations header was removed and the page updated to revision v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T20:42:45.000Z thumbnail image
  6. Check
    75 days ago
    Change Detected
    Summary
    Revision updated from v3.2.0 to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-25T10:21:57.000Z thumbnail image
  7. Check
    82 days ago
    Change Detected
    Summary
    The page no longer displays the government funding status notice. All study details, locations, and eligibility criteria remain unchanged.
    Difference
    0.4%
    Check dated 2025-11-18T06:45:40.000Z thumbnail image

Stay in the know with updates to Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.